Product Name :
Fleroxacin
Description:
Fleroxacin, a quinolone, is a bactericidal drug that inhibits bacterial DNA gyrase and topoisomerase IV. Like other quinolones and fluoroquinolones the compound eradicates bacteria by interfering with DNA replication (bacterial DNA replication, transcription, repair and recombination). Fleroxacin is active against many Gram-positive and Gram-negative bacteria.
CAS:
79660-72-3
Molecular Weight:
369.34
Formula:
C17H18F3N3O3
Chemical Name:
6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Smiles :
CN1CCN(CC1)C1=C(F)C2=C(C=C1F)C(=O)C(=CN2CCF)C(O)=O
InChiKey:
XBJBPGROQZJDOJ-UHFFFAOYSA-N
InChi :
InChI=1S/C17H18F3N3O3/c1-21-4-6-22(7-5-21)15-12(19)8-10-14(13(15)20)23(3-2-18)9-11(16(10)24)17(25)26/h8-9H,2-7H2,1H3,(H,25,26)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.Malonyl CoA NF-κB
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Fleroxacin, a quinolone, is a bactericidal drug that inhibits bacterial DNA gyrase and topoisomerase IV.Nivolumab medchemexpress Like other quinolones and fluoroquinolones the compound eradicates bacteria by interfering with DNA replication (bacterial DNA replication, transcription, repair and recombination).PMID:32697111 Fleroxacin is active against many Gram-positive and Gram-negative bacteria.|Product information|CAS Number: 79660-72-3|Molecular Weight: 369.34|Formula: C17H18F3N3O3|Synonym:|Quinodis|Megalocin|AM-833|Megalone|AM833|AM 833|Chemical Name: 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid|Smiles: CN1CCN(CC1)C1=C(F)C2=C(C=C1F)C(=O)C(=CN2CCF)C(O)=O|InChiKey: XBJBPGROQZJDOJ-UHFFFAOYSA-N|InChi: InChI=1S/C17H18F3N3O3/c1-21-4-6-22(7-5-21)15-12(19)8-10-14(13(15)20)23(3-2-18)9-11(16(10)24)17(25)26/h8-9H,2-7H2,1H3,(H,25,26)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: 0.1 M NaOH : 9.17 mg/mL (24.83 mM; ultrasonic and adjust pH to 12 with NaOH)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vivo:|Fleroxacin (Ro 23-6240) is a new trifluorinated quinolone exhibiting high activity against a broad spectrum of gram-negative and gram-positive bacteria. Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g., maximum concentration of 2.3 micrograms/ml after an oral dose of 200 mg). Fleroxacin (Ro 23-6240) is effective against Haemophilus ducreyi in vitro. Fleroxacin (Ro 23-6240), 200 or 400 mg as a single oral dose, is efficacious therapy for microbiologically proven chancroid in patients who do not have concurrent HIV-1 infection. Among HIV-1-infected men, a single dose of 200 or 400 mg of fleroxacin is inadequate therapy for chancroid.|References:|Weidekamm, E., et al., Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. Antimicrob Agents Chemother, 1987. 31(12): p. 1909-14.MacDonald, K.S., et al., Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya. Antimicrob Agents Chemother, 1989. 33(5): p. 612-4.Products are for research use only. Not for human use.|